• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    A Look Into Healthcare Sector Value Stocks

    1/8/24 9:44:03 AM ET
    $CYH
    $MEIP
    $SCYX
    $VYGR
    Hospital/Nursing Management
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYH alert in real time by email

    What is a Value Stock?

    A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

    Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching:

    1. Exicure (NASDAQ:XCUR) - P/E: 0.33
    2. Voyager Therapeutics (NASDAQ:VYGR) - P/E: 7.63
    3. MEI Pharma (NASDAQ:MEIP) - P/E: 0.96
    4. SCYNEXIS (NASDAQ:SCYX) - P/E: 1.27
    5. Community Health Sys (NYSE:CYH) - P/E: 1.85

    Exicure saw an increase in earnings per share from -0.7 in Q1 to $-0.68 now. Voyager Therapeutics saw a decrease in earnings per share from -0.51 in Q2 to $-0.59 now. MEI Pharma's earnings per share for Q1 sits at $8.46, whereas in Q4, they were at -1.51. Most recently, SCYNEXIS reported earnings per share at $-0.04, whereas in Q2 earnings per share sat at $2.46. Most recently, Community Health Sys reported earnings per share at $-0.33, whereas in Q2 earnings per share sat at $-0.22.

    The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

    Get the next $CYH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYH
    $MEIP
    $SCYX
    $VYGR

    CompanyDatePrice TargetRatingAnalyst
    Community Health Systems Inc.
    $CYH
    7/24/2025$3.00Buy → Hold
    Jefferies
    Voyager Therapeutics Inc.
    $VYGR
    1/10/2025Overweight
    Cantor Fitzgerald
    Voyager Therapeutics Inc.
    $VYGR
    12/2/2024$12.00Buy
    Citigroup
    Voyager Therapeutics Inc.
    $VYGR
    11/29/2024$7.00 → $11.00Outperform
    Wedbush
    Community Health Systems Inc.
    $CYH
    11/25/2024$5.00 → $2.50Equal Weight → Underweight
    Wells Fargo
    Community Health Systems Inc.
    $CYH
    11/22/2024Mkt Perform → Underperform
    Raymond James
    Voyager Therapeutics Inc.
    $VYGR
    10/16/2024$15.00Outperform
    Leerink Partners
    MEI Pharma Inc.
    $MEIP
    7/23/2024Buy → Hold
    Laidlaw
    More analyst ratings

    $CYH
    $MEIP
    $SCYX
    $VYGR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hitron Systems Inc. bought $8,700,000 worth of shares (2,900,000 units at $3.00), increasing direct ownership by 669% to 3,333,333 units (SEC Form 4)

    4 - EXICURE, INC. (0001698530) (Issuer)

    3/26/25 5:41:19 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Dgp Co., Ltd. bought $711,669 worth of shares (237,223 units at $3.00), increasing direct ownership by 39% to 849,223 units (SEC Form 4)

    4 - EXICURE, INC. (0001698530) (Issuer)

    9/16/24 9:41:12 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Angulo Gonzalez David bought $27,400 worth of shares (20,000 units at $1.37), increasing direct ownership by 4% to 507,871 units (SEC Form 4)

    4 - SCYNEXIS INC (0001178253) (Issuer)

    9/16/24 8:00:27 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYH
    $MEIP
    $SCYX
    $VYGR
    SEC Filings

    View All

    SEC Form 8-K filed by Voyager Therapeutics Inc.

    8-K - Voyager Therapeutics, Inc. (0001640266) (Filer)

    2/12/26 8:00:38 AM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Community Health Systems Inc. filed SEC Form 8-K: Leadership Update

    8-K - COMMUNITY HEALTH SYSTEMS INC (0001108109) (Filer)

    2/11/26 4:30:02 PM ET
    $CYH
    Hospital/Nursing Management
    Health Care

    Exicure Inc. filed SEC Form 8-K: Leadership Update

    8-K - EXICURE, INC. (0001698530) (Filer)

    2/10/26 4:25:41 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYH
    $MEIP
    $SCYX
    $VYGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Voyager to Present at Upcoming Investor Conferences

    LEXINGTON, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences: Guggenheim Emerging Outlook: Biotech Summit 2026: Fireside chat at 1:00 p.m. ET on Wednesday, February 11, 2026, in New York, NY.Oppenheimer 36th Annual Healthcare Life Sciences Conference: Fireside chat at 3:20 p.m. ET on Thursday, February 26, 2026.TD Cowen 46th Annual Health Care Conference: Fireside chat at 1:10 p.m. ET on Monday, March 2, 2026, in Boston, MA.Leerink Global Healthcare Conference 2026: Firesid

    2/9/26 8:00:00 AM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

    REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication of results from a prior Phase 2 clinical study evaluating burixafor (GPC-100/TG-0054), a highly selective CXCR4 inhibitor, in the journal Annals of Hematology. The manuscript, titled "Burixafor, a CXCR4 Inhibitor with a Differentiated Kinetics Profile: Results of a Phase 2 Study for Rapid Cell Mobilization in Multiple Myeloma and Lymphoma Patients Undergoing Transplant," reports results from a 12-participant, multi-center, open-label Phase 2 study (NCT02104427) evaluating burixafor in c

    2/5/26 7:00:00 AM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Community Health Systems to Webcast Fourth Quarter and Year-End 2025 Conference Call

    Community Health Systems, Inc. (NYSE:CYH) today announced that it will webcast its fourth quarter and year-end 2025 conference call. The Company will issue a press release announcing its results on Wednesday February 18, 2026, after the regular close of trading. The conference call is scheduled to begin at 10:00 a.m. Central Time, 11:00 a.m. Eastern Time, on Thursday, February 19, 2026. During this call, Community Health Systems will review the Company's financial and operating results for the fourth quarter and full year ended December 31, 2025. A live webcast of the conference call will be available online at https://www.chs.net/investor-relations/investor-tools/webcasts/. An online r

    2/4/26 11:00:00 AM ET
    $CYH
    Hospital/Nursing Management
    Health Care

    $CYH
    $MEIP
    $SCYX
    $VYGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $CYH
    $MEIP
    $SCYX
    $VYGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    COO & CBO Swartz Robin sold $17,591 worth of shares (4,569 units at $3.85), decreasing direct ownership by 2% to 210,078 units (SEC Form 4)

    4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)

    2/11/26 4:32:27 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Sandrock Alfred sold $46,086 worth of shares (12,192 units at $3.78), decreasing direct ownership by 2% to 509,989 units (SEC Form 4)

    4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)

    2/11/26 4:30:56 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Scientific Officer Carter Todd Alfred sold $13,571 worth of shares (3,525 units at $3.85), decreasing direct ownership by 2% to 153,193 units (SEC Form 4)

    4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)

    2/11/26 4:30:40 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Community Health downgraded by Jefferies with a new price target

    Jefferies downgraded Community Health from Buy to Hold and set a new price target of $3.00

    7/24/25 7:25:45 AM ET
    $CYH
    Hospital/Nursing Management
    Health Care

    Cantor Fitzgerald initiated coverage on Voyager Therapeutics

    Cantor Fitzgerald initiated coverage of Voyager Therapeutics with a rating of Overweight

    1/10/25 9:15:32 AM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citigroup initiated coverage on Voyager Therapeutics with a new price target

    Citigroup initiated coverage of Voyager Therapeutics with a rating of Buy and set a new price target of $12.00

    12/2/24 7:04:18 AM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CYH
    $MEIP
    $SCYX
    $VYGR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

    Submission status for SCYNEXIS, INC's drug BREXAFEMME (ORIG-1) with active ingredient IBREXAFUNGERP has changed to 'Approval' on 06/01/2021. Application Category: NDA, Application Number: 214900, Application Classification: Type 1 - New Molecular Entity

    6/2/21 11:20:46 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

    Submission status for SCYNEXIS, INC's drug BREXAFEMME (SUPPL-1) with active ingredient IBREXAFUNGERP has changed to 'Approval' on 06/01/2021. Application Category: NDA, Application Number: 214900, Application Classification: Type 1 - New Molecular Entity

    6/2/21 9:57:42 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYH
    $MEIP
    $SCYX
    $VYGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

    SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

    11/14/24 7:07:26 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

    SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

    11/14/24 6:13:11 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CYH
    $MEIP
    $SCYX
    $VYGR
    Leadership Updates

    Live Leadership Updates

    View All

    Community Health Systems Appoints Kevin Hammons Chief Executive Officer and Jason Johnson Chief Financial Officer

    Community Health Systems, Inc. (NYSE:CYH) (the "Company" or "CHS") announced today that the Company's Board of Directors has appointed Kevin Hammons to chief executive officer and Jason Johnson to chief financial officer, effective immediately. Hammons and Johnson have been serving in these roles on an interim basis since October 1, 2025. Hammons was also appointed to serve as a member of the Board. "I'm honored to lead the CHS team during a time when we see significant opportunities to advance clinical services, quality and patient care, deeply engage with employees and physicians, and create lasting value for all of our communities and stakeholders," said Kevin Hammons, chief executive o

    12/10/25 4:15:00 PM ET
    $CYH
    Hospital/Nursing Management
    Health Care

    Tim Hingtgen to Retire as Chief Executive Officer of Community Health Systems

    Kevin Hammons to Become Interim CEO and Jason Johnson to Become Interim CFO Community Health Systems, Inc. (the "Company") ("CHS") (NYSE:CYH) and its Board of Directors announced today that Tim Hingtgen will retire from his position as chief executive officer and as a member of the Board, effective September 30, 2025. It is anticipated that Hingtgen will enter into a consulting agreement in which he will continue to advise the Company's management team on issues related to healthcare operations and other Company matters. Kevin Hammons, who currently serves as president and chief financial officer, will assume the role of interim chief executive officer upon Hingtgen's retirement, and Ja

    7/23/25 4:16:00 PM ET
    $CYH
    Hospital/Nursing Management
    Health Care

    Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

    Exicure, Inc. (NASDAQ:XCUR, "the Company", "Exicure")), today announced that in connection with the change of control transaction approved by the stockholders at the Special Meeting of the Stockholders on December 17, 2024 (the "Change of Control"), the stockholders of the Company approved a second investment of $8.7 million from HiTron Systems Inc. ("HiTron"), a publicly listed company (KOSPI) in South Korea. This investment is expected to close within a few days depending on regulatory approvals. Also, on December 19, 2024, the Board of Directors (the "Board") of the Company changed the authorized number of directors comprising the Board to nine directors and appointed four new directors

    12/20/24 4:42:00 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYH
    $MEIP
    $SCYX
    $VYGR
    Financials

    Live finance-specific insights

    View All

    Community Health Systems to Webcast Fourth Quarter and Year-End 2025 Conference Call

    Community Health Systems, Inc. (NYSE:CYH) today announced that it will webcast its fourth quarter and year-end 2025 conference call. The Company will issue a press release announcing its results on Wednesday February 18, 2026, after the regular close of trading. The conference call is scheduled to begin at 10:00 a.m. Central Time, 11:00 a.m. Eastern Time, on Thursday, February 19, 2026. During this call, Community Health Systems will review the Company's financial and operating results for the fourth quarter and full year ended December 31, 2025. A live webcast of the conference call will be available online at https://www.chs.net/investor-relations/investor-tools/webcasts/. An online r

    2/4/26 11:00:00 AM ET
    $CYH
    Hospital/Nursing Management
    Health Care

    Exicure, Inc. Reports Third Quarter 2025 Financial Results

    REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the fiscal quarter ended September 30, 2025. Third Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $4.4 million as of September 30, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and development expenses were $0.9 million for the quarter ended September 30, 2025, as compared to $0 for the quarter ended September 30, 2024. The increase in R&D expense of $0.9 million for the three months ended September 30, 2025 was due to incurring research and developmen

    11/7/25 4:00:00 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Community Health Systems, Inc. Announces Third Quarter Ended September 30, 2025 Results

    Community Health Systems, Inc. (NYSE:CYH) (the "Company") today announced financial and operating results for the three and nine months ended September 30, 2025. The following highlights the financial and operating results for the three months ended September 30, 2025. Net operating revenues totaled $3.087 billion. Net income attributable to Community Health Systems, Inc. stockholders was $130 million, or $0.96 per share (diluted), compared to net loss of $(391) million, or $(2.95) per share (diluted), for the same period in 2024. Excluding the adjusting items as presented in the table in footnote (e) on page 15, net income attributable to Community Health Systems, Inc. stockholders

    10/23/25 4:15:00 PM ET
    $CYH
    Hospital/Nursing Management
    Health Care